These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 4177687)

  • 21. [Intravenous thrombolysis in the acute phase of myocardial infarct].
    de Fuster C
    Soins Cardiol; 1985 May; (27):47-8. PubMed ID: 3848147
    [No Abstract]   [Full Text] [Related]  

  • 22. Antiplatelet therapy in coronary heart disease. Emerging strategies for the treatment and prevention of acute myocardial infarction.
    Becker RC
    Arch Pathol Lab Med; 1993 Jan; 117(1):89-96. PubMed ID: 8418769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anticoagulants].
    Coelho E
    Rev Hosp Clin Fac Med Sao Paulo; 1968 Jul; 23(4):217-28. PubMed ID: 4175980
    [No Abstract]   [Full Text] [Related]  

  • 24. Is fibrinolysis critical for acute coronary syndromes?
    Kluft C; Andreotti F
    Ital Heart J; 2001 Sep; 2(9):639-40. PubMed ID: 11666088
    [No Abstract]   [Full Text] [Related]  

  • 25. Disseminated intravascular coagulation. Heparin, anticoagulant and urokinase in experimental nephritic in mice.
    Humair LM
    Proc R Soc Med; 1968 Nov; 61(11 Part 1):1137-8. PubMed ID: 4177534
    [No Abstract]   [Full Text] [Related]  

  • 26. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
    Sabatine MS; Morrow DA; Montalescot G; Dellborg M; Leiva-Pons JL; Keltai M; Murphy SA; McCabe CH; Gibson CM; Cannon CP; Antman EM; Braunwald E;
    Circulation; 2005 Dec; 112(25):3846-54. PubMed ID: 16291601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anticoagulant treatment in myocardial infarct].
    Bukowski Z
    Wiad Lek; 1971 Mar; 24(5):433-7. PubMed ID: 4251758
    [No Abstract]   [Full Text] [Related]  

  • 28. [Antithrombotic therapy in ischemic heart disease].
    Lengyel M
    Orv Hetil; 1989 Dec; 130(49):2643-4. PubMed ID: 2601950
    [No Abstract]   [Full Text] [Related]  

  • 29. [Temporary connection between coronary thrombosis and myocardial infarct].
    Emmrich P
    Z Gesamte Inn Med; 1970 Jan; 25(1):10-7. PubMed ID: 5522124
    [No Abstract]   [Full Text] [Related]  

  • 30. [Results of long-term administration of anticoagulants in patients with myocardial infarct and coronary arterial disease without infarct].
    Korolko A
    Pol Tyg Lek; 1972 Nov; 27(48):1897-900. PubMed ID: 4118936
    [No Abstract]   [Full Text] [Related]  

  • 31. Current status of activation markers in ischemic heart disease: markers of coagulation activation.
    Merlini PA; Ardissino D
    Thromb Haemost; 1997 Jul; 78(1):276-9. PubMed ID: 9198166
    [No Abstract]   [Full Text] [Related]  

  • 32. [Shifts in coagulating and fibrinolytic activity of the blood following the administration of nerobol in patients with coronary atherosclerosis].
    Kratovskaia OV; Zalaldinova NB; Afaunova VI; Denisova TP; Lebedeva SN
    Ter Arkh; 1972 Sep; 44(9):29-31. PubMed ID: 4660396
    [No Abstract]   [Full Text] [Related]  

  • 33. Management of evolving myocardial infarction by intracoronary thrombolysis and subsequent aorta-coronary bypass.
    Krebber HJ; Mathey D; Kuck KJ; Kalmar P; Rodewald G
    J Thorac Cardiovasc Surg; 1982 Feb; 83(2):186-93. PubMed ID: 6977071
    [No Abstract]   [Full Text] [Related]  

  • 34. Fibrinolytic enhancement by stanozolol: a double blind trial.
    Davidson JF; Lochhead M; McDonald GA; McNicol GP
    Br J Haematol; 1972 May; 22(5):543-59. PubMed ID: 4555715
    [No Abstract]   [Full Text] [Related]  

  • 35. [Compensatory-adaptive reactions of the blood coagulating and fibrinolytic systems in the main cardiovascular diseases].
    Gritsiuk AI
    Vrach Delo; 1976 Jan; (1):13-20. PubMed ID: 128903
    [No Abstract]   [Full Text] [Related]  

  • 36. Heparin in acute coronary syndromes.
    Peverill RE
    Lancet; 2000 Aug; 356(9229):593-4. PubMed ID: 10950255
    [No Abstract]   [Full Text] [Related]  

  • 37. [The optimization of the results with the use of thrombolytic therapy in acute myocardial infarct (I)].
    Cerveró Martí A
    Med Clin (Barc); 1993 May; 100(17):668-74. PubMed ID: 8497174
    [No Abstract]   [Full Text] [Related]  

  • 38. [Advantages and hazards of drug treatment in surgery. Anticoagulants and fibrinolytic agents].
    Gross R
    Chirurg; 1968 May; 39(5):201-8. PubMed ID: 4974339
    [No Abstract]   [Full Text] [Related]  

  • 39. [Enoxaparin in the treatment of acute myocardial infarction].
    Iavelov IS
    Ter Arkh; 1999; 71(9):80-3. PubMed ID: 10553633
    [No Abstract]   [Full Text] [Related]  

  • 40. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
    Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
    Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.